Evolution of Health Technology Assessment in Indonesia: Supply Landscape, Implementation, and Future Directions

References

• World Health Organization (WHO). Using health technology assessment for universal health coverage and reimbursement systems. Geneva, Switzerland: World Health Organization (WHO); 2015 Nov 2 [accessed 2024 Apr 1]. hta_november_meeting_report_final.pdf(who.int).
   Google Scholar
• Chalkidou K, Glassman A, Marten R, Vega J, Teerawattananon Y, Tritasavit N, Gyansa-Lutterodt M, Seiter A, Kieny MP, Hofman K, et al. Priority-setting for achieving universal health coverage. Bull World Health Organ. 2016 June 1;94(6):462–10. doi:10.2471/BLT.15.155721.
   PubMed Web of Science ®Google Scholar
• Chalkidou K, Li R, Culyer AJ, Glassman A, Hofman KJ, Teerawattananon Y. Health technology assessment: global advocacy and local realities comment on “priority setting for universal health coverage: we need evidence-informed deliberative processes, not just more evidence on cost-effectiveness. Int J Health Policy Manag. 2017 Apr 1;6(4):233–36. doi:10.15171/ijhpm.2016.118.
   PubMed Web of Science ®Google Scholar
• Teerawattananon Y, Painter C, Dabak S, Ottersen T, Gopinathan U, Chola L, Chalkidou K, Culyer AJ. Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making. Cost Eff Resour Alloc. 2021 Sep 22;19(1):62. doi:10.1186/s12962-021-00308-1.
   PubMed Web of Science ®Google Scholar
• MacQuilkan K, Baker P, Downey L, Ruiz F, Chalkidou K, Prinja S, Zhao K, Wilkinson T, Glassman A, Hofman K. Strengthening health technology assessment systems in the global south: a comparative analysis of the HTA journeys of China, India and South Africa. Glob Health Action. 2018;11(1):1527556. doi:10.1080/16549716.2018.1527556.
   PubMed Web of Science ®Google Scholar
• Pitt C, Vassall A, Teerawattananon Y, Griffiths UK, Guinness L, Walker D, Foster N, Hanson K. Foreword: health economic evaluations in low- and middle-income countries: methodological issues and challenges for priority setting. Health Economics. 2016 Feb;25 Suppl 1(Suppl Suppl 1):1–5. doi:10.1002/hec.3319.
   PubMedGoogle Scholar
• Peraturan Presiden No. 12/2013 junto No. 82/2018 tentang Jaminan Kesehatan Nasional. Jakarta, 2013 and 2018.
   Google Scholar
• Keputusan Menteri Kesehatan No.171/Menkes/SK/IV/2014 junto No. 01.07/MENKES 6192/2020 tentang Komite Penilaian Teknologi Kesehatan (KPTK). Jakarta, 2014 and 2020.
   Google Scholar
• Sharma M, Teerawattananon Y, Luz A, Li R, Rattanavipapong W, Dabak S. Institutionalizing evidence-informed priority setting for universal health coverage: lessons from Indonesia. Inquiry. 2020 Jan;57:46958020924920. doi:10.1177/0046958020924920.
   PubMed Web of Science ®Google Scholar
• Chavarina KK, Faradiba D, Sari EN, Wang Y, Teerawattananon Y. Health economic evaluations for Indonesia: a systematic review assessing evidence quality and adherence to the Indonesian Health Technology Assessment (HTA) guideline. Lancet Reg Health Southeast Asia. 2023 Mar 31;13:100184. doi:10.1016/j.lansea.2023.100184.
   PubMedGoogle Scholar
• Chavarina KK, Faradiba D, Teerawattananon Y. Navigating HTA implementation: a review of Indonesia’s revised HTA guideline. Lancet Reg Health Southeast Asia. 2023 Sep 11;17:100280. doi:10.1016/j.lansea.2023.100280.
   PubMedGoogle Scholar
• Putri S, Saldi SRF, Khoe LC, Setiawan E, Megraini A, Santatiwongchai B, Nugraha RR, Permanasari VY, Nadjib M, Sastroasmoro S, et al. Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. BMC Cancer. 2023 Aug 8;23(1):731. doi:10.1186/s12885-023-11253-y.
   PubMed Web of Science ®Google Scholar
• Putri S, Nugraha RR, Pujiyanti E, Thabrany H, Hasnur H, Istanti ND, Evasari D, Afiatin. Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model. BMC Res Notes. 2022 Dec 6;15(1):359. doi:10.1186/s13104-022-06252-4.
   PubMed Web of Science ®Google Scholar
• Putri S, Setiawan E, Saldi SRF, Khoe LC, Sari ER, Megraini A, Nadjib M, Sastroasmoro S, Armansyah A. Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. BMC Health Serv Res. 2022 Apr 25;22(1):553. doi:10.1186/s12913-022-07956-w.
   PubMed Web of Science ®Google Scholar
• Kristin E, Endarti D, Khoe LC, Taroeno-Hariadi KW, Trijayanti C, Armansyah A, Sastroasmoro S. Economic evaluation of adding bevacizumab to chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia. Asian Pac J Cancer Prev. 2021 June 1;22(6):1921–26. doi:10.31557/APJCP.2021.22.6.1921.
   PubMedGoogle Scholar
• Keputusan Menteri Kesehatan No. HK.02.02/MENKES/523/2015 tentang formularium nasional. Jakarta; 2015.
   Google Scholar
• Peraturan Menteri Kesehatan No. 63/2014 tentang Pengadaan Obat Berdasarkan Katalog Elektronik (e-Catalogue). Jakarta; 2014 Sep.
   Google Scholar
• Keputusan Menteri Kesehatan No. HK.02.02/MENKES/524/2015 junto HK.02.02/MENKES/636/2016 tentang Formularium Nasional. Jakarta, 2015 and 2016. PERATURAN (kemkes.go.id).
   Google Scholar
• Indonesia Health Technology Assessment Committee (InaHTAC). Health Technology Assessment (HTA) guideline. Jakarta: Ministry of Health; 2017.
   Google Scholar
• Kajian kebijakan pengadaan obat untuk program Jaminan Kesehatan Nasional 2014-2018. TNP2K. 2020.
   Google Scholar
• Keputusan Menteri Kesehatan 2197/2023 tentang Formularium Nasional. Jakarta; 2023.
   Google Scholar
• Situational analysis of health technology as the first step to develop HTA roadmap in Indonesia. Depok: CHEPS UI, MOH and WHO; 2021.
   Google Scholar
• Health Technology Assessment Indonesia: Annual review 2022. Pusat Kebijakan Pembiayaan dan Desentralisasi Kesehatan, Badan Kebijakan Pembangunan Kesehatan, Kementerian Kesehatan. Jakarta; 2022.
   Google Scholar
• Suryawati S, Nadjib M, Hidayat B, Syam FA, Purwantyastuti A, Kristin E, Thobari At J, Syarkati A, Fortuna HP, Siti ML, et al. General guideline for health technology assessment in Indonesia.Wiweko B, Suryawati S, editors. Jakarta: Health Policy Agency Publishing Company (BKPK Publishing Company); 2022. p. 74.
   Google Scholar
• World Health Organization Commission on Macroeconomics and Health: Macroeconomics and health: investing in health for economic development. Macroeconomics and health: investing in health for economic development (who.Int). Geneva: World Health Organization; 2001 [accessed 2024 May 6].
   Google Scholar
• Hutubessy R, Chisholm D, Edejer T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003 Dec 19. 1(1):8. doi:10.1186/1478-7547-1-8.
   PubMedGoogle Scholar
• Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies. Value In Health. 2018 Jul;21(7):759–61. doi:10.1016/j.jval.2017.12.016.
   PubMed Web of Science ®Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016 Dec 1;94(12):925–30. doi:10.2471/BLT.15.164418.
   PubMed Web of Science ®Google Scholar
• Chi YL, Blecher M, Chalkidou K, Culyer A, Claxton K, Edoka I, Glassman A, Kreif N, Jones I, Mirelman AJ, et al. What next after GDP-based cost-effectiveness thresholds? Gates Open Res. 2020 Nov 30;4:176. doi:10.12688/gatesopenres.13201.1.
   PubMedGoogle Scholar
• Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one- and three-times GDP per capita cost-effectiveness thresholds. Health Policy Planning. 2017 Feb;32(1):141–45. doi:10.1093/heapol/czw096.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015 Feb 1;93(2):118–24. doi:10.2471/BLT.14.138206.
   PubMed Web of Science ®Google Scholar
• Teerawattananon Y, Teo YY, Dabak S, Rattanavipapong W, Isaranuwatchai W, Wee HL, Luo N, Morton A. Tackling the 3 big challenges confronting health technology assessment development in Asia: a commentary. Value Health Reg Issues. 2020 May;21:66–68. doi:10.1016/j.vhri.2019.07.001.
   PubMedGoogle Scholar
• Keputusan Menteri Kesehatan RI No. HK.01.07/MENKES/274/2018 tentang Uji Coba Tata Laksana Penyakit Ginjal Tahap Akhir dalam Rangka Peningkatan Cakupan Pelayanan CAPD.
   Google Scholar
• Alasan BPJS Kesehatan Hapus Obat Kanker Trastuzumab. CNN Indonesia. 2018 [accessed 2024 Apr 2]. https://www.cnnindonesia.com/ekonomi/20180717102756-78-314718/alasan-bpjs-kesehatan-hapus-obat-kanker-trastuzumab.
   Google Scholar
• Trastuzumab Masuk dalam Daftar Obat Kanker pada Fornas 2024. Media Indonesia 2024. accessed 2024 Apr 2]. https://mediaindonesia.com/humaniora/659574/trastuzumab-masuk-dalam-daftar-obat-kanker-pada-fornas-2024.
   Google Scholar
• Novaes HM, Soárez PC. Health technology assessment (HTA) organizations: dimensions of the institutional and political framework. Cad Saude Publica. 2016 Nov 3;32Suppl 2(Suppl 2):e00022315. English, Portuguese. doi:10.1590/0102-311X00022315.
   PubMedGoogle Scholar